Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. reports a minor adjustment to its upcoming cash dividend schedule. The company previously declared a cash dividend of $0.25 per ordinary share, or approximately NIS 0.77 per share, totaling about $14.4 million, under its newly adopted annual cash dividend policy.
The dividend will now be paid on April 7, 2026, instead of April 6, 2026, to shareholders of record at the close of business on March 23, 2026. All other terms of the dividend, including amount and record date, remain unchanged. Kamada also reiterates forward-looking statements about its intention to pay annual cash dividends of at least 50% of its annual net income, subject to various business, financial, and regulatory risks.
KAMADA LTD director Lilach Payorski has filed an initial Form 3 disclosing option holdings in the company. The filing reports four grants of options to purchase 7,500 ordinary shares each, covering a total of 30,000 shares at an exercise price of $6.15 per share.
The options are exercisable using a net-exercise method and all expire on June 22, 2029. The tranches become exercisable on December 22, 2023, December 22, 2024, December 22, 2025 and December 22, 2026, respectively. Exercise prices are presented in U.S. dollars based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd. director Assaf Itshayek filed a Form 3 reporting existing holdings of stock options for Ordinary Shares. The filing lists four option positions, each covering 4,000 underlying Ordinary Shares at an exercise price of $6.26 per share, expiring on March 7, 2030, with different future exercise dates from September 7, 2024 through September 7, 2027. The options are exercisable using a net-exercise method, and the U.S. dollar exercise prices reflect a convenience translation from New Israeli Shekels based on the Bank of Israel exchange rate as of March 13, 2026.
KAMADA LTD filed an amended Schedule 13G/A reporting beneficial ownership positions as of 12/31/2025. The filing shows Gov Financial Holdings Ltd. holds 1,455,458 ordinary shares (2.52%), Insight Capital Ltd. holds 1,346,334 shares (2.33%), and Leon Recanati beneficially owns 3,481,937 shares (6.04%).
The summary states Mr. Recanati directly holds 631,145 shares and options exercisable for 49,000 shares within 60 days of 12/31/2025. The filing uses 57,686,056 ordinary shares as the base for percentage calculations. The amendment is signed by Mr. Recanati on 03/16/2026.
Kamada Ltd executive Boris Gorelik filed an initial statement of beneficial ownership, reporting stock option holdings rather than new trades. The filing lists several grants of options to purchase Ordinary Shares, including tranches for 3,750 underlying shares at an exercise price of $9.4300 per share expiring on February 11, 2027, and 15,000 underlying shares at $5.0400 per share expiring on January 16, 2029. Additional option grants cover 15,000 underlying shares at an exercise price of $7.1400 per share expiring on October 22, 2035. The options are exercisable using a net-exercise method, and all exercise prices shown in the filing are convenience translations from New Israeli Shekels into U.S. dollars based on the Bank of Israel’s representative exchange rate as of March 13, 2026.
Kamada Ltd Chief Executive Officer Amir London reported his equity holdings in the company. He directly owns 61,875 Ordinary Shares and also holds several grants of options to purchase Ordinary Shares, each covering 100,000 underlying shares at exercise prices of $6.15 and $7.55 per share, with expirations in 2029 and 2035. The options are exercisable using a net-exercise method, meaning only the in-the-money value is settled in shares rather than paying cash for the full exercise price.
Kamada Ltd executive Orit Pinchuk, VP Regulatory Affairs, filed an initial Form 3 reporting her equity position in the company. She directly holds 12,133 Ordinary Shares.
She also holds several option grants to purchase Ordinary Shares, including one grant exercisable for 15,000 shares at $6.15 per share, expiring on August 28, 2028, and additional grants each covering 15,000 shares at $7.55 per share with an expiration date of October 22, 2035 and different future exercise dates. The options are exercisable using a net-exercise method, and the U.S. dollar exercise prices are convenience translations from NIS based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd executive Beladev Shavit, VP Plasma Operations, has filed an initial ownership report. Shavit directly holds 3,418 Ordinary Shares and several option grants to purchase additional Ordinary Shares at exercise prices of $6.15 and $7.55, with expirations between 2028 and 2035. These options are exercisable using a net-exercise method, and the U.S. dollar exercise prices reflect translation from NIS based on the Bank of Israel’s representative exchange rate as of March 13, 2026.
Kamada Ltd VP of Marketing & Sales Hanni Neheman has filed an initial ownership report showing ordinary shares and stock options in the company. The filing lists direct ownership of 3,417 ordinary shares and several option grants over ordinary shares with exercise prices of $6.15 and $7.55 per share, expiring between 2028 and 2035. The options are exercisable using a net-exercise method, and the exercise prices shown in U.S. dollars reflect a translation from New Israeli Shekels based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd director David Tsur has filed an initial ownership report showing direct holdings of 607,929 Ordinary Shares of the company.
He also holds several grants of options to purchase Ordinary Shares, each covering either 6,625 or 7,500 underlying shares at exercise prices of $7.5200 and $6.1500, with expiration dates ranging from September 25, 2026 to June 22, 2029. According to the footnotes, these options are exercisable using a net-exercise method, and the exercise prices shown in U.S. dollars reflect a convenience translation from NIS based on the Bank of Israel representative exchange rate as of March 13, 2026.